Cargando…
Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
BACKGROUND: The effectiveness of glucose-lowering drugs (GLDs) is unknown among patients with dementia. OBJECTIVE: To analyze all-cause mortality among users of six GLDs in dementia and dementia-free subjects, respectively. METHODS: This was a longitudinal open-cohort registry-based study using data...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028644/ https://www.ncbi.nlm.nih.gov/pubmed/35034902 http://dx.doi.org/10.3233/JAD-215337 |
_version_ | 1784691672786927616 |
---|---|
author | Secnik, Juraj Xu, Hong Schwertner, Emilia Hammar, Niklas Alvarsson, Michael Winblad, Bengt Eriksdotter, Maria Garcia-Ptacek, Sara Religa, Dorota |
author_facet | Secnik, Juraj Xu, Hong Schwertner, Emilia Hammar, Niklas Alvarsson, Michael Winblad, Bengt Eriksdotter, Maria Garcia-Ptacek, Sara Religa, Dorota |
author_sort | Secnik, Juraj |
collection | PubMed |
description | BACKGROUND: The effectiveness of glucose-lowering drugs (GLDs) is unknown among patients with dementia. OBJECTIVE: To analyze all-cause mortality among users of six GLDs in dementia and dementia-free subjects, respectively. METHODS: This was a longitudinal open-cohort registry-based study using data from the Swedish Dementia Registry, Total Population Register, and four supplemental registers providing data on dementia status, drug usage, confounders, and mortality. The cohort comprised 132,402 subjects with diabetes at baseline, of which 11,401 (8.6%) had dementia and 121,001 (91.4%) were dementia-free. Subsequently, comparable dementia – dementia-free pairs were sampled. Then, as-treated and intention-to-treat exposures to metformin, insulin, sulfonylurea, dipeptidyl-peptidase-4 inhibitors, glucagon-like peptide-1 analogues (GLP-1a), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) were analyzed in the parallel dementia and dementia-free cohorts. Confounding was addressed using inverse-probability weighting and propensity-score matching, and flexible parametric survival models were used to produce hazard ratios (HR) and 95% confidence intervals (CI) of the association between GLDs and all-cause mortality. RESULTS: In the as-treated models, increased mortality was observed among insulin users with dementia (HR 1.34 [95%CI 1.24–1.45]) as well as in dementia-free subjects (1.54 [1.10–1.55]). Conversely, sulfonylurea was associated with higher mortality only in dementia subjects (1.19 [1.01–1.42]). GLP-1a (0.44 [0.25–0.78]) and SGLT-2i users with dementia (0.43 [0.23–0.80]) experienced lower mortality compared to non-users. CONCLUSION: Insulin and sulfonylurea carried higher mortality risk among dementia patients, while GLP-1a and SGLT-2i were associated with lower risk. GLD-associated mortality varied between dementia and comparable dementia-free subjects. Further studies are needed to optimize GLD use in dementia patients. |
format | Online Article Text |
id | pubmed-9028644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-90286442022-05-06 Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia Secnik, Juraj Xu, Hong Schwertner, Emilia Hammar, Niklas Alvarsson, Michael Winblad, Bengt Eriksdotter, Maria Garcia-Ptacek, Sara Religa, Dorota J Alzheimers Dis Research Article BACKGROUND: The effectiveness of glucose-lowering drugs (GLDs) is unknown among patients with dementia. OBJECTIVE: To analyze all-cause mortality among users of six GLDs in dementia and dementia-free subjects, respectively. METHODS: This was a longitudinal open-cohort registry-based study using data from the Swedish Dementia Registry, Total Population Register, and four supplemental registers providing data on dementia status, drug usage, confounders, and mortality. The cohort comprised 132,402 subjects with diabetes at baseline, of which 11,401 (8.6%) had dementia and 121,001 (91.4%) were dementia-free. Subsequently, comparable dementia – dementia-free pairs were sampled. Then, as-treated and intention-to-treat exposures to metformin, insulin, sulfonylurea, dipeptidyl-peptidase-4 inhibitors, glucagon-like peptide-1 analogues (GLP-1a), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) were analyzed in the parallel dementia and dementia-free cohorts. Confounding was addressed using inverse-probability weighting and propensity-score matching, and flexible parametric survival models were used to produce hazard ratios (HR) and 95% confidence intervals (CI) of the association between GLDs and all-cause mortality. RESULTS: In the as-treated models, increased mortality was observed among insulin users with dementia (HR 1.34 [95%CI 1.24–1.45]) as well as in dementia-free subjects (1.54 [1.10–1.55]). Conversely, sulfonylurea was associated with higher mortality only in dementia subjects (1.19 [1.01–1.42]). GLP-1a (0.44 [0.25–0.78]) and SGLT-2i users with dementia (0.43 [0.23–0.80]) experienced lower mortality compared to non-users. CONCLUSION: Insulin and sulfonylurea carried higher mortality risk among dementia patients, while GLP-1a and SGLT-2i were associated with lower risk. GLD-associated mortality varied between dementia and comparable dementia-free subjects. Further studies are needed to optimize GLD use in dementia patients. IOS Press 2022-03-08 /pmc/articles/PMC9028644/ /pubmed/35034902 http://dx.doi.org/10.3233/JAD-215337 Text en © 2022 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Secnik, Juraj Xu, Hong Schwertner, Emilia Hammar, Niklas Alvarsson, Michael Winblad, Bengt Eriksdotter, Maria Garcia-Ptacek, Sara Religa, Dorota Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia |
title | Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia |
title_full | Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia |
title_fullStr | Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia |
title_full_unstemmed | Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia |
title_short | Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia |
title_sort | glucose-lowering medications and post-dementia survival in patients with diabetes and dementia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028644/ https://www.ncbi.nlm.nih.gov/pubmed/35034902 http://dx.doi.org/10.3233/JAD-215337 |
work_keys_str_mv | AT secnikjuraj glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia AT xuhong glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia AT schwertneremilia glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia AT hammarniklas glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia AT alvarssonmichael glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia AT winbladbengt glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia AT eriksdottermaria glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia AT garciaptaceksara glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia AT religadorota glucoseloweringmedicationsandpostdementiasurvivalinpatientswithdiabetesanddementia |